Clinical trials: Healthy Volunteers; High Cholesterol
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density…
- Trial name
- NCT05384262
- Testing
- AZD0780, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyslipidemias, Familial Hypercholesterolemia
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial…
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT03747224
- Testing
- ARO-ANG3, sterile normal saline (0.9% NaCl)
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10582 following single and multiple dose administration to healthy subjects and subjects with Mildly Elevated LDL-C.
- Trial name
- NCT07777003
- Testing
- HS-10582
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Hypercholesterolemia
Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers
The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.
- Trial name
- NCT02587364
- Testing
- Gemcabene 50 mg, Gemcabene 150 mg, Gemcabene 450 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypercholesterolemia
Bioequivalence Study Of Pediatric Appropriate Formulation
To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.
- Trial name
- NCT00758004
- Testing
- Atorvastatin, Atorvastatin pediatric appropriate formulation
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
High Cholesterol
Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects
- Trial name
- NCT07347678
- Testing
- RN5681
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Hyperlipidemia
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets)…
- Trial name
- NCT00652431
- Testing
- Vytorin + Niaspan, Vytorin, Niaspan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyslipidemias, Familial Hypercholesterolemia
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05851066
- Testing
- VSA003, 0.9% NaCl
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Visirna Therapeutics HK Limited
Healthy Volunteers; High Cholesterol
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol).
- Trial name
- NCT05333107
- Testing
- NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Primary Objective: Injection Site Tolerability Secondary Objectives: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01443650
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917644
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides).
- Trial name
- NCT06452771
- Testing
- ALN-ANG3
- Where
- New Zealand
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia, Dyslipidemia
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
- Trial name
- NCT07655960
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Healthy Participants, Dyslipidemia
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a)…
- Trial name
- NCT06980428
- Testing
- AZD4954
- Where
- 6 sites in United States
- Volunteers
- 136 people
- Sponsor
- AstraZeneca
Hypercholesterolemia and Hyperlipidemia
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration.
- Trial name
- NCT06837077
- Testing
- SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.